Spinal Cord Homogenate Induced EAE in (BALB/c x SJL)F1 Mice

Hooke runs most commonly-used EAE models. Click here for an overview of EAE and a list of models offered.

This direct EAE model is induced by immunization with mouse whole spinal cord homogenate emulsified in CFA in crossbred (BALB/c x SJL)F1 mice, followed by a single injection of pertussis toxin.

It was once commonly used to evaluate efficacy and equivalence of generic glatiramer acetate [1], however our experience (with concurrence from the FDA) is that other models are better suited for that purpose.

Copaxone (Teva Pharmaceuticals) is used as a positive control and reference compound. Treatment is prophylactic, the model is 28 days long.

Glatiramer acetate potency can alternatively be evaluated by analysis of cytokine production by T cells isolated from immunized mice; Hooke offers ELISA, cytokine bead assay (CBA), and Luminex assays, which are all suitable for this analysis.

Please contact Hooke at or with questions or for a quotation.

Typical results in this model

Spinal cord homogenate induced EAE in (BALB/c x SJL)F1 mice

Spinal cord homogenate induced EAE in (BALB/c x SJL)F1 mice - scoresSpinal cord homogenate induced EAE in (BALB/c x SJL)F1 mice - weight

Treatment Median day
of onset
p value
(onset)
MMS
± SEM
p value
(MMS)
Relapse incidence p value
(incidence)
Vehicle 10.0 3.50 ± 0.19 81.8%
Glatiramer acetate 13.0 <0.0001 1.83 ± 0.33 0.0015 33.3% 0.0162
Treatment Relapse MMS
± SEM
p value
(relapse MMS)
End score
± SEM
p value
(end score)
End weight (%)
± SEM
p value
(end weight)
Vehicle 2.83 ± 0.32 1.92 ± 0.43 91.6 ± 1.8
Glatiramer acetate 0.96 ± 0.36 0.0015 0.79 ± 0.34 0.0172 103.8 ± 2.3 0.0004

Tissue collection and end-of-study analysis

Hooke offers an extensive set of tissue collection and analysis options. Click here for more information.

References

[1] Lando Z et al. J Immunol 123:2156 (1979)

See also